Literature DB >> 21412071

Mucosal colonization by metastatic carcinoma in the gastrointestinal tract: a potential mimic of primary neoplasia.

Jeannelyn S Estrella1, Tsung-Teh Wu, Asif Rashid, Susan C Abraham.   

Abstract

The gastrointestinal (GI) tract is a common site for both primary and metastatic carcinomas. Distinguishing the two can occasionally be difficult, particularly when metastatic tumor reaches the mucosal surface. Features that are typically used to make this distinction include the presence of an adenomatous precursor lesion, regional lymph node involvement, and gross configuration of the tumor. However, we recently encountered 2 index cases of metastatic carcinoma in the small intestine (1 from the colorectum and 1 of endocervical origin) that were initially misinterpreted as primary small bowel carcinomas because of apparent in situ growth in the mucosal surface resembling polypoid, adenomatous precursor lesions. We, therefore, studied 100 GI resections from 1987 to 2009 that were reported to show mucosal involvement by metastatic carcinoma, and compared the histologic features with a control group of 29 primary small bowel adenocarcinomas. Gross descriptions and histologic sections were evaluated for the following: (1) tumor spread along an intact basement membrane of villi/crypts (mucosal colonization), (2) resemblance to an adenoma/precursor lesion, (3) gross configuration of the tumor, (4) lymphovascular invasion, and (5) regional lymph node involvement in the metastatic site. Metastatic sites included the small intestine (n=74), colorectum (n=16), or both (n=10). Primary tumors were GI (n=55, with 47 from colorectum), gynecologic (n=28), pulmonary (n=8), genitourinary (n=6), head and neck (n=2), and breast (n=1). Overall, 42 (42%) of the metastases that reached the mucosal surface of the bowel showed at least focal mucosal colonization, 26% resembled a precursor adenoma, 62% had regional lymph node positivity, and only 24% cases showed a classic serosal-based configuration. In 4 cases (2 of GI origin and 2 of gynecologic origin), metastatic tumors were initially interpreted as new primaries by the pathologist (n=2) or clinicians (n=2). Metastatic carcinomas originating from the GI tract were significantly more likely to show mucosal colonization (60% vs. 20%, P<0.0001) and resemblance to a precursor lesion (45% vs. 2%, P<0.0001) than other primary tumors. In a comparison between 29 primary small bowel carcinomas and 41 metastatic colorectal carcinomas in the small bowel, metastatic tumors were distinguished by a higher prevalence of multiple lesions (0% vs. 39%, P<0.0001), whereas small bowel primaries were more likely to show high tumor grade (41% vs. 17%, P=0.03). There were no significant differences in the mean age (61.4 y vs. 60.9 y), number of male participants (69% vs. 56%), growth along basement membranes (62% vs. 63%), apparent precursor lesion (55% vs. 46%), lymphovascular invasion (69% vs. 73%), or lymph node positivity (68% vs. 37.5%, P=0.065). These results confirm that metastatic carcinomas involving the mucosal surface of the intestines frequently exhibit gross and histologic features, which mimic second primaries, especially when they originate from the GI tract. In situ growth and presence of an apparent adenoma cannot be taken as prima facie evidence of a primary neoplasm.

Entities:  

Mesh:

Year:  2011        PMID: 21412071     DOI: 10.1097/PAS.0b013e318211b3d2

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  9 in total

Review 1.  [Secondary tumors of the gastrointestinal tract].

Authors:  C Langner
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

2.  Squamous cell carcinoma of the small bowel manifesting as a jejunal perforation: a case report.

Authors:  Der Sheng Sun; Ok Ran Shin; Young Mi Ku; Young-Seok Kim; Kyung-Jin Seo
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 3.  American Registry of Pathology Expert Opinions: Evaluation of poorly differentiated malignant neoplasms on limited samples - Gastrointestinal mucosal biopsies.

Authors:  Andrew M Bellizzi; Elizabeth A Montgomery; Jason L Hornick
Journal:  Ann Diagn Pathol       Date:  2019-11-15       Impact factor: 2.090

4.  Intrabiliary growth of liver metastases: clinicopathologic features, prevalence, and outcome.

Authors:  Jeannelyn S Estrella; Mohammad L Othman; Melissa W Taggart; Stanley R Hamilton; Steven A Curley; Asif Rashid; Susan C Abraham
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

5.  Unique presentations of invasive lobular breast cancer: a case series.

Authors:  Muhammad Tariq Shakoor; Samia Ayub; Ramesh Mohindra; Zunaira Ayub; Abdul Ahad
Journal:  Int J Biomed Sci       Date:  2014-12

6.  Lynch syndrome-related small intestinal adenocarcinomas.

Authors:  Sun-Young Jun; Eui-Jin Lee; Mi-Ju Kim; Sung Min Chun; Young Kyung Bae; Soon Uk Hong; Jene Choi; Joon Mee Kim; Kee-Taek Jang; Jung Yeon Kim; Gwang Il Kim; Soo Jin Jung; Ghilsuk Yoon; Seung-Mo Hong
Journal:  Oncotarget       Date:  2017-03-28

7.  Metachronous rectal metastasis from primary transverse colon cancer: a case report.

Authors:  Shigehiro Kojima; Tsuguo Sakamoto; Yuko Nagai; Masayuki Honda; Fumihiro Ogawa
Journal:  Surg Case Rep       Date:  2018-08-09

8.  Colorectal metastasis to the gallbladder mimicking a primary gallbladder malignancy: histopathological and molecular characteristics.

Authors:  Tessa J J de Bitter; Ragna L A van der Linden; Shannon van Vliet; Fieke Weren; Daoud Sie; Bauke Ylstra; Hans C van der Linden; Nikki Knijn; Marjolijn J L Ligtenberg; Rachel S van der Post; Femke Simmer; Iris D Nagtegaal
Journal:  Histopathology       Date:  2019-07-18       Impact factor: 5.087

Review 9.  Metastasis in the gallbladder: does literature reflect reality?

Authors:  Tessa J J de Bitter; Daan M Trapman; Femke Simmer; Niek Hugen; Elise A J de Savornin Lohman; Philip R de Reuver; Joanne Verheij; Iris D Nagtegaal; Rachel S van der Post
Journal:  Virchows Arch       Date:  2022-03-31       Impact factor: 4.535

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.